查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2086172

神經性疼痛治療​​市場：按產品類型、給藥途徑、適應症和分銷管道分類的全球市場預測，2026-2032年

Neuropathic Pain Drug Market by Product Type, Route Of Administration, Indication, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，神經性疼痛治療​​市場將成長至 119.5 億美元，複合年成長率為 8.10%。

主要市場統計數據
基準年 2025 69.3億美元
預計年份：2026年 73.6億美元
預測年份 2032 119.5億美元
複合年成長率 (%) 8.10%

神經病變疼痛治療​​藥物市場介紹

神經病變疼痛的治療發展正從廣泛的症狀治療轉向以精準醫療為導向的方法，以解決糖尿病神經病變、帶狀皰疹後遺症神經痛、化療引起的周邊神經病變、脊髓損傷疼痛、三叉神經痛、神經神經線病變和其他神經損傷綜合症等問題。流行病學文獻估計，神經病變疼痛在一般人群中的盛行率約為7-10%，這給醫療保健系統、保險公司和生命科學公司帶來了沉重的臨床和經濟負擔。

神經病變疼痛領域的變革性變化

糖尿病盛行率上升、癌症倖存者人數增加、人口老化以及與手術、創傷、感染疾病和自體免疫疾病相關的神經損傷病例增多，正在重塑神經病變疼痛藥物市場格局。根據國際糖尿病聯盟（IDF）統計，2021年全球有5.37億成年人患有糖尿病，預計到2030年這一數字將增加至6.43億，到2045年將達到7.83億。這凸顯了糖尿病周邊神經病變治療藥物持續存在的臨床需求。

人工智慧對神經病變疼痛治療​​發展的累積影響

人工智慧 (AI) 透過加速標靶辨識、化合物篩檢、轉化生物標記分析和臨床試驗可行性研究，正累積改善神經病變疼痛的藥物研發。 AI 驅動的自然語言處理技術可以分析電子健康記錄，識別出未被充分診斷​​的神經病變疼痛患者群體；機器學習模型則可用於根據症狀叢集、合併症、既往藥物反應、多重用藥風險以及治療中斷的可能性對患者進行分層。

主要區域洞察：亞太地區、北美地區、拉丁美洲地區、歐洲地區、中東和非洲地區

亞太地區（包括中國、印度、日本、韓國和澳洲）是全球最具活力的需求中心之一，其促進因素包括糖尿病患者數量龐大、人口老齡化、疼痛管理需求不斷成長以及品牌學名藥和創新藥物的可及性提高。日本和澳洲擁有成熟的醫保報銷體系和完善的臨床指南，而中國和印度擁有龐大的病患群體，因此需要製定在地化的定價策略、實證醫學證據、醫生教育和分銷策略。

重點區域洞察：東協、海灣合作理事會、歐盟、金磚國家、七國集團與北約

由於糖尿病盛行率上升以及城市地區神經科、內分泌科和疼痛管理服務的普及，東協市場的重要性日益凸顯。市場進入策略若能結合醫師教育、價格合理的製劑、完善的藥物安全監測系統、與當地經銷商的合作，則最為有效。鑑於海灣合作打入市場策略（GCC）都市區糖尿病和肥胖症負擔沉重，對專科醫療保健系統的投資不斷增加，以及品牌藥若能獲得臨床證據支持、建立健全的競標體系並採取符合當地法規的註冊策略，則具有巨大的市場滲透潛力，因此該地區蘊藏著巨大的機遇。

對主要神經病變疼痛治療​​市場關鍵國家的深入分析。

美國是神經病變疼痛藥物商業化的核心市場，這得益於其龐大的糖尿病確診患者群體、完善的專科處方體系、成熟的臨床試驗生態系統以及對減少鴉片類藥物使用的疼痛治療方案的旺盛需求。然而，支付方監管、預先核准和階梯療法可能會限制高級產品的普及。加拿大提供穩定的報銷途徑和基於指南的醫療保健體系，而墨西哥則受益於糖尿病管理的擴展、對私人醫療保健的需求以及品牌學名藥使用量的增加，從而獲得了更多藥物。巴西是拉丁美洲重要的市場機遇，這得益於其高慢性病負擔以及公私混合的醫療保健體系。在巴西，定價、本地證據以及納入處方藥目錄是至關重要的因素。

為神經病變疼痛治療​​領域的領導企業提供實用建議

產業領導企業應優先考慮差異化的臨床特徵，而非單純的療效提升。研發項目應展現顯著的鎮痛效果、改善睡眠和功能、良好的耐受性、降低停藥率，以及對特定亞型神經病變疼痛的適用性。雖然在糖尿病周邊神經病變和帶狀皰疹後遺症神經痛方面，強力的證據仍然具有重要的商業性價值，但化療引起的周邊神經病變、三叉神經痛、脊髓損傷相關疼痛以及其他存在未滿足治療需求的疾病，也可能支持延長產品的生命週期。

調查方法

本執行摘要基於二手研究，參考了同行評審的神經病變疼痛文獻、臨床指南、監管批准、公共衛生資料集以及來自國際疼痛學會、糖尿病聯盟、公共衛生機構、藥品監管機構和國家衛生技術評估機構等認可組織的資訊。

結論

由於糖尿病、老化、癌症復健、神經系統疾病以及限制鴉片類藥物使用的治療策略等因素，人們對更安全、更有效的治療方法的需求日益成長，因此，神經病變疼痛藥物市場預計將保持重要的戰略地位。儘管現有藥物仍然必不可少，但在持續療效、耐受性、患者分層、治療依從性和疾病特異性證據方面仍存在未被滿足的需求。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：神經性疼痛治療​​市場：依產品類型分類

  • 抗驚厥藥物
    • Carbamazepine
    • Gabapentin
    • 拉莫三嗪
    • Pregabalin
  • 抗憂鬱症
    • SNRI
      • Duloxetine
      • 文拉法辛
    • TCA
      • 阿米替林
      • 去甲替林
  • 鴉片類藥物
    • Tapentadol
    • 特拉馬多爾
  • 外用製劑
    • 辣椒素
    • 雙氯芬酸鈉酸凝膠
    • Lidocaine貼劑

第8章：神經性疼痛治療​​藥物市場：依給藥途徑分類

  • 靜脈
  • 口服
  • 外用
  • 經皮給藥

第9章：神經性疼痛治療​​市場：依適應症分類

  • 化療引起的神經病變
  • 糖尿病神經病變
  • HIV相關神經病變
  • 帶狀皰疹後遺症神經痛

第10章：神經性疼痛治療​​市場：依通路分類

  • 醫院和藥房
  • 零售藥房
  • 專科診所

第11章：神經性疼痛治療​​市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章：神經性疼痛治療​​市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章：神經性疼痛治療​​市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • AcelRx Therapeutics, Inc.
  • Bausch Health Companies Inc.
  • Eli Lilly and Company
  • Endo International plc
  • Grunenthal GmbH
  • Hikma Pharmaceuticals PLC
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-036C5CF3B4DE

The Neuropathic Pain Drug Market is projected to grow by USD 11.95 billion at a CAGR of 8.10% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.93 billion
Estimated Year [2026] USD 7.36 billion
Forecast Year [2032] USD 11.95 billion
CAGR (%) 8.10%

Neuropathic Pain Drug Market Introduction

Neuropathic pain drug development is moving from broad symptomatic management toward precision-oriented therapies that address diabetic neuropathy, postherpetic neuralgia, chemotherapy-induced peripheral neuropathy, spinal cord injury pain, trigeminal neuralgia, radiculopathy, and other nerve-injury syndromes. Epidemiological literature commonly estimates neuropathic pain prevalence at approximately 7% to 10% of the general population, making it a major clinical and economic burden for health systems, payers, and life sciences organizations.

Current treatment is anchored by guideline-supported options such as gabapentinoids, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, topical lidocaine, and high-concentration capsaicin, while opioids are increasingly restricted because of safety, dependency, and policy concerns. For pharmaceutical innovators, this creates a clear opportunity for differentiated neuropathic pain medications with improved tolerability, faster onset, disease-specific efficacy, lower discontinuation, and evidence suitable for value-based reimbursement.

Transformative Shifts in the Neuropathic Pain Landscape

The neuropathic pain drug landscape is being reshaped by the rising prevalence of diabetes, cancer survivorship, aging populations, and nerve injury associated with surgery, trauma, infections, and autoimmune disorders. The International Diabetes Federation reported 537 million adults living with diabetes in 2021, with projections rising to 643 million by 2030 and 783 million by 2045, supporting sustained clinical need for diabetic peripheral neuropathy therapies.

At the same time, clinical practice is moving away from one-size-fits-all analgesia. Regulators and payers increasingly expect robust patient-reported outcomes, functional improvement, comparative effectiveness, and safety evidence. Pipeline strategies are therefore prioritizing non-opioid mechanisms, sodium channel modulation, calcium channel modulation, neuroinflammation pathways, cannabinoid-related approaches where permitted, and combination regimens that can address heterogeneous neuropathic pain biology.

Cumulative Impact of Artificial Intelligence in Neuropathic Pain Drug Development

Artificial intelligence is cumulatively improving neuropathic pain drug discovery by accelerating target identification, compound screening, translational biomarker analysis, and clinical trial feasibility. AI-enabled natural language processing can analyze electronic health records to identify underdiagnosed neuropathic pain cohorts, while machine learning models can help stratify patients by symptom cluster, comorbidity, prior medication response, polypharmacy risk, and likelihood of treatment discontinuation.

The greatest near-term value is expected in trial design, pharmacovigilance, and real-world evidence generation rather than fully autonomous drug discovery. AI can support adaptive recruitment, detect safety signals earlier, and integrate wearable, claims, imaging, omics, and patient-reported data. For industry leaders, governance remains essential because pain outcomes are subjective, datasets can be biased, and regulatory acceptance requires transparency, validation, auditability, and reproducibility.

Key Regional Insights: Asia-Pacific, North America, Latin America, Europe, Middle East & Africa

Asia-Pacific is one of the most dynamic demand centers because China, India, Japan, South Korea, and Australia combine large diabetes populations, aging demographics, expanding pain specialty care, and growing access to branded generics and innovative medicines. Japan and Australia have mature reimbursement systems and stronger clinical guideline adoption, while China and India offer substantial patient-volume potential but require localized pricing, evidence generation, physician education, and distribution strategies.

North America remains the most commercially advanced region, led by the United States and Canada, where established diagnosis pathways, specialist networks, payer scrutiny, and opioid-sparing policies favor evidence-backed non-opioid neuropathic pain drugs. Latin America is gaining relevance as Brazil and Mexico expand diabetes management and private healthcare access, although affordability and formulary inclusion remain central to uptake.

Europe benefits from strong clinical research infrastructure, centralized regulatory pathways, and widespread use of health technology assessment, but access varies by country-level reimbursement criteria and cost-effectiveness thresholds. The Middle East, particularly high-income Gulf health systems, is shaped by significant diabetes and obesity burdens, investment in specialty care, and tender-led procurement. Africa represents a longer-term access opportunity, where underdiagnosis, limited pain specialist availability, medicine affordability, and primary-care capacity influence the adoption of neuropathic pain therapies.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7 & NATO

ASEAN markets are gaining relevance as diabetes prevalence rises and access to neurology, endocrinology, and pain management services expands in urban centers. Entry strategies are strongest where organizations combine physician education, affordable formulations, pharmacovigilance readiness, and local distributor partnerships. The GCC presents a high-priority opportunity because diabetes and obesity burdens are significant, health systems are investing in specialty care, and branded medicines can gain traction when supported by clinical evidence, tender readiness, and compliant local registration strategies.

The European Union offers scale through harmonized regulatory science and established clinical guidance, but country-specific reimbursement remains decisive for patient access. BRICS countries provide large patient pools, expanding clinical trial activity, and manufacturing advantages, particularly in China, India, and Brazil, yet pricing pressure and procurement requirements are intense. G7 markets remain innovation leaders with strong clinical trial capacity, advanced pharmacovigilance systems, and high evidentiary expectations. NATO-aligned markets overlap substantially with North America and Europe, where supply-chain resilience, secure health data infrastructure, medicine availability, and regulatory alignment are increasingly strategic priorities for neuropathic pain drug commercialization.

Key Country Insights Across Major Neuropathic Pain Drug Markets

The United States is the anchor country for neuropathic pain drug commercialization because of its large diagnosed diabetes population, specialty prescribing base, established clinical trial ecosystem, and strong demand for opioid-sparing pain therapies, though payer controls, prior authorization, and step therapy can limit premium uptake. Canada offers stable reimbursement pathways and guideline-driven care, while Mexico provides growing access opportunities supported by expanding diabetes management, private healthcare demand, and broader use of branded generics. Brazil is a major Latin American opportunity due to its large chronic disease burden and mixed public-private healthcare system, where pricing, local evidence, and formulary access are decisive.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine high clinical standards with rigorous reimbursement assessment; Germany is particularly important for early benefit evaluation, while the United Kingdom emphasizes cost-effectiveness through national health technology appraisal. France, Italy, and Spain require strong clinical differentiation and budget-impact evidence, while Russia remains a complex access market shaped by localization, procurement dynamics, and regulatory requirements.

In Asia-Pacific, China and India offer the largest patient-volume opportunities because of diabetes burden, aging populations, and expanding healthcare access, but pricing, local data, and distribution depth are critical. Japan and South Korea provide high-value innovation markets with advanced clinical practice, aging demographics, and strong expectations for quality and safety evidence. Australia supports evidence-based adoption through structured reimbursement, specialist-led care, and clear payer scrutiny, making it important for therapies that can demonstrate clinically meaningful functional and quality-of-life benefits.

Actionable Recommendations for Neuropathic Pain Drug Leaders

Industry leaders should prioritize differentiated clinical profiles, not incremental claims. Development programs need to demonstrate meaningful pain reduction, sleep and function improvement, tolerability, reduced discontinuation, and applicability to defined neuropathic pain subtypes. Strong evidence in diabetic peripheral neuropathy and postherpetic neuralgia remains commercially important, while chemotherapy-induced peripheral neuropathy, trigeminal neuralgia, spinal cord injury pain, and other underserved conditions can support lifecycle expansion.

Commercial teams should align trial endpoints with payer expectations, build real-world evidence early, and prepare country-specific value dossiers. Organizations should also invest in AI-enabled patient identification, pharmacovigilance, adherence analytics, and digital outcome capture while maintaining rigorous data governance. Regional strategies should balance premium launches in G7 markets with affordable access models, branded generics, and partnerships in BRICS, ASEAN, Latin America, the Middle East, and Africa.

Research Methodology

This executive summary is based on secondary research from peer-reviewed neuropathic pain literature, clinical guidelines, regulatory labels, public health datasets, and recognized institutional sources, including international pain associations, diabetes federations, public health agencies, medicines regulators, and national health technology assessment bodies.

The methodology integrates epidemiology, approved treatment standards, pipeline direction, reimbursement dynamics, regional access conditions, artificial intelligence adoption, and technology-enabled evidence generation trends. Insights were triangulated across clinical, regulatory, commercial, and health-system evidence to avoid unsupported market claims and to provide practical intelligence for drug developers, investors, and commercialization teams.

Conclusion

The neuropathic pain drug market is positioned for sustained strategic importance as diabetes, aging, cancer survivorship, neurological disorders, and opioid-sparing treatment policies expand the need for safer and more effective therapies. While existing medicines remain essential, unmet needs persist in efficacy durability, tolerability, patient stratification, treatment adherence, and condition-specific evidence.

Organizations that combine differentiated non-opioid mechanisms, AI-supported development, robust real-world evidence, and localized market access strategies will be best placed to compete. Success will depend on proving value not only through pain score improvement but also through measurable gains in function, sleep, adherence, safety, quality of life, and health-system efficiency.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Neuropathic Pain Drug Market, by Product Type

  • 7.1. Anticonvulsants
    • 7.1.1. Carbamazepine
    • 7.1.2. Gabapentin
    • 7.1.3. Lamotrigine
    • 7.1.4. Pregabalin
  • 7.2. Antidepressants
    • 7.2.1. SNRIs
      • 7.2.1.1. Duloxetine
      • 7.2.1.2. Venlafaxine
    • 7.2.2. TCAs
      • 7.2.2.1. Amitriptyline
      • 7.2.2.2. Nortriptyline
  • 7.3. Opioids
    • 7.3.1. Tapentadol
    • 7.3.2. Tramadol
  • 7.4. Topical Agents
    • 7.4.1. Capsaicin
    • 7.4.2. Diclofenac Gel
    • 7.4.3. Lidocaine Patch

8. Neuropathic Pain Drug Market, by Route Of Administration

  • 8.1. Intravenous
  • 8.2. Oral
  • 8.3. Topical
  • 8.4. Transdermal

9. Neuropathic Pain Drug Market, by Indication

  • 9.1. Chemotherapy-Induced Neuropathy
  • 9.2. Diabetic Neuropathy
  • 9.3. HIV-Associated Neuropathy
  • 9.4. Post-Herpetic Neuralgia

10. Neuropathic Pain Drug Market, by Distribution Channel

  • 10.1. Hospitals Pharmacy
  • 10.2. Retail Pharmacies
  • 10.3. Specialty Clinics

11. Neuropathic Pain Drug Market, by Region

  • 11.1. Asia-Pacific
  • 11.2. North America
  • 11.3. Latin America
  • 11.4. Europe
  • 11.5. Middle East
  • 11.6. Africa

12. Neuropathic Pain Drug Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Neuropathic Pain Drug Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Concentration Analysis, 2025
    • 14.1.1. Concentration Ratio (CR)
    • 14.1.2. Herfindahl Hirschman Index (HHI)
  • 14.2. Recent Developments & Impact Analysis, 2025
  • 14.3. Product Portfolio Analysis, 2025
  • 14.4. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. AcelRx Therapeutics, Inc.
  • 15.2. Bausch Health Companies Inc.
  • 15.3. Eli Lilly and Company
  • 15.4. Endo International plc
  • 15.5. Grunenthal GmbH
  • 15.6. Hikma Pharmaceuticals PLC
  • 15.7. Mylan N.V.
  • 15.8. Novartis AG
  • 15.9. Pfizer Inc.
  • 15.10. Sanofi S.A.
  • 15.11. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEUROPATHIC PAIN DRUG MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL NEUROPATHIC PAIN DRUG MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL NEUROPATHIC PAIN DRUG MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL NEUROPATHIC PAIN DRUG MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEUROPATHIC PAIN DRUG MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL NEUROPATHIC PAIN DRUG MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTICONVULSANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTICONVULSANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CARBAMAZEPINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CARBAMAZEPINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CARBAMAZEPINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GABAPENTIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GABAPENTIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL LAMOTRIGINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL LAMOTRIGINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL LAMOTRIGINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PREGABALIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PREGABALIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PREGABALIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTIDEPRESSANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTIDEPRESSANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTIDEPRESSANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SNRIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SNRIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SNRIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DULOXETINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DULOXETINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DULOXETINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL VENLAFAXINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL VENLAFAXINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL VENLAFAXINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TCAS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TCAS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TCAS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL AMITRIPTYLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL AMITRIPTYLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL AMITRIPTYLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NORTRIPTYLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NORTRIPTYLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NORTRIPTYLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL OPIOIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL OPIOIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL OPIOIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TAPENTADOL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TAPENTADOL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TAPENTADOL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TRAMADOL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TRAMADOL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TRAMADOL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TOPICAL AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TOPICAL AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TOPICAL AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CAPSAICIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CAPSAICIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CAPSAICIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DICLOFENAC GEL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DICLOFENAC GEL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DICLOFENAC GEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL LIDOCAINE PATCH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL LIDOCAINE PATCH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL LIDOCAINE PATCH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL TRANSDERMAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL TRANSDERMAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL TRANSDERMAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CHEMOTHERAPY-INDUCED NEUROPATHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CHEMOTHERAPY-INDUCED NEUROPATHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CHEMOTHERAPY-INDUCED NEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HIV-ASSOCIATED NEUROPATHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HIV-ASSOCIATED NEUROPATHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HIV-ASSOCIATED NEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL POST-HERPETIC NEURALGIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL POST-HERPETIC NEURALGIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL POST-HERPETIC NEURALGIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HOSPITALS PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL HOSPITALS PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL HOSPITALS PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 175. GCC NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 176. GCC NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. GCC NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 178. GCC NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 179. GCC NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 180. GCC NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 181. GCC NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 182. GCC NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 183. GCC NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 184. GCC NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 185. GCC NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 208. G7 NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. G7 NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. G7 NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 211. G7 NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 212. G7 NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 213. G7 NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 214. G7 NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 215. G7 NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 216. G7 NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 217. G7 NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 218. G7 NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. NATO NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 220. NATO NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. NATO NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 222. NATO NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 223. NATO NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 224. NATO NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 225. NATO NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 226. NATO NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 227. NATO NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 228. NATO NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 229. NATO NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 230. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 242. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 243. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 245. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 246. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 247. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 248. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 249. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 250. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 251. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 252. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 253. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 254. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 256. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 257. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 258. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 259. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 260. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 261. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 262. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 263. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 264. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 265. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 267. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 268. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 269. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 270. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 271. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 272. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 273. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 274. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 286. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 287. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 289. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 290. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 291. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 292. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 293. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 294. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 295. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 296. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 297. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 298. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 300. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 301. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 302. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 303. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 304. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 305. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 306. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 307. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 308. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 309. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 310. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 311. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 312. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 313. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 314. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 315. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 316. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 317. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 318. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 319. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 320. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 321. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 322. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 323. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 324. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 325. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 326. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 327. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 328. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 329. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 330. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 331. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 332. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 333. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 334. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 335. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 336. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 337. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 338. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 339. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 340. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 341. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 342. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 343. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 344. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 345. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 346. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 347. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 348. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 349. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 350. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 351. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 352. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 353. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 354. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 355. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 356. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 357. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 358. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 359. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 360. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 361. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 362. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 363. JAPAN NEUROPATHIC PAIN DRU